MyRisk®
Hereditary Cancer Test

Understanding your patient's MyRisk® result

A guide to interpreting risk and taking action

Myriad genetics

Health. Illuminated.®

The Myriad Genetics MyRisk® Hereditary Cancer Test result has three main sections which are summarized in the banner on the first page. Throughout the report, these sections can be identified by the title on the top left of each page of the report.

1. Genetic Test Result
2. Clinical & Cancer Family history information
3. Medical Management Tool

1 Genetic Test Result

The MyRisk® Hereditary Cancer Test looks at multiple genes associated with hereditary cancer risk. When a gene has a clinically significant mutation, or harmful change, there is a higher chance for certain cancers to develop. A list of the genes evaluated on your test can be found in this section of the report. The gene table on our website includes information about each gene and the cancers with which it is associated. For eligible patients, information about a patient's breast cancer risk will be included in this section.

Interpreting a “Negative” result

No clinically significant mutations were found in any of the genes analyzed as part of your patient’s testing. This does not mean that your patient has no cancer risk; it means that we did not identify a harmful genetic change in any of the genes analyzed. Additionally, the patient cannot pass a clinically significant mutation in these genes to their children.

CONFIDENTIAL

54501229

MyRisk® Hereditary Cancer Test

MyRisk Management Tool

MyRisk® Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER

Test HCP, MD
Test Medical Center
6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN

Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

PATIENT

Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1981
Patient ID: Patient id
Gender: Female
Accession #: 07007251-BLD
Requisition #: 90026818

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

BREAST CANCER RISKSCORE®: REMAINING LIFETIME RISK 12.1%

See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED

Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may not be consistent with the general population. See Information below.

Interpreting an “Elevated” result

No clinically significant mutation was identified in the tested genes of your patient, but medical management may need to change due to personal, family history and/or other genomic risk factors. This elevated result typicallyis shown because the patient’s RiskScore® and/or Tyrer-Cuzick breast cancer risk model finding is at or above a 20% remaining lifetime risk for developing breast cancer.


CONFIDENTIAL

Integrated BRACAnalysis® with MyRisk® Hereditary Cancer Test

MyRisk Management Tool

MyRisk® Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

PATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1982
Patient ID: Patient id
Gender: Female
Accession #: 07007255-BLD
Requisition #: 90026826

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

BREAST CANCER RISKSCORE®: REMAINING LIFETIME RISK 35.3%
This level of risk is at or above 20% threshold for consideration of modified medical management.
See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

BREAST CANCER RISKSCORE®

THIS BREAST CANCER RISKSCORE® IS ASSOCIATED WITH THE FOLLOWING CANCER RISKS:

Interpreting a “Positive” result

Myriad identified a genetic change that is likely or definitively known to increase the risk(s) of cancer. It is important to encourage your patients to share these results with their close relatives. Consult the MyRisk® Management Tool help to create a plan to best manage your patient’s risks.


CONFIDENTIAL

MyRisk® Hereditary Cancer Test

MyRisk Management Tool

MyRisk® Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

PATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1976
Patient ID: Patient id
Gender: Female
Accession #: 07007253-BLD
Requisition #: 90026822

GENETIC RESULT: POSITIVE - CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

GENE
Gene Name

MUTATION
Mutation Name

THIS GENETIC TEST RESULT IS ASSOCIATED WITH THE FOLLOWING CANCER RISKS:
HIGH RISK: Breast, Ovarian, Pancreatic

Interpreting a “Variant of Uncertain Clinical Significance”

When identified, variants of uncertain significance (VUS) are reported and they can be seen on Negative, Elevated Risk or Positive MyRisk® reports. A VUS is a genetic change that has unknown effect on cancer risk. A VUS is not considered to be clinically actionable, so medical care decisions should not be made based on a VUS. If updated, actionable information is available about your patient's specific VUS, that information will be shared with you.


CONFIDENTIAL

MyRisk® Hereditary Cancer Test

MyRisk Management Tool

MyRisk® Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

PATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1981
Patient ID: Patient id
Gender: Female
Accession #: 07007251-BLD
Requisition #: 90026818

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

BREAST CANCER RISKSCORE®: REMAINING LIFETIME RISK 12.1%
See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may still be increased over the general population. See information below.

Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.

2 Clinical & Cancer Family History Information

The Clinical & Cancer Family History Information section reviews the patient's clinical and family history information that was submitted. Certain types of cancer in the family, or cancers diagnosed at early ages can indicate that someone may have an elevated cancer risk, even if no clinically significant mutations are found.

3 Medical Management Tool

The MyRisk® Management Tool provides a summary of guideline-based recommendations for suggested changes to your patient's medical care based on the test results and their personal/family history. If your patient received a RiskScore® and/or a Tyrer-Cuzick breast cancer risk assessment, the Management Tool will show their estimated lifetime risk of developing breast cancer. Risk below 20% is generally not considered clinically actionable, while risk at or above 20% suggests that increased breast surveillance is recommended.

Your patients have access to a MyRisk Hereditary Cancer Test Result consult with a board-certified genetic counselor at no additional cost

(Tear Here and Provide to Patient)

What is a MyRisk test result consult?

A phone-based consult with a certified genetic counselor is an educational session included with your MyRisk Hereditary Cancer Test results. A consult can help you better understand your results and answer any questions that you may have.

What is a genetic counselor?

Genetic counselors are specially trained and certified by the American Board of Genetic Counseling and can provide the information and support you may need to better understand the results of your genetic test. At Myriad, your test includes a consult with a Myriad genetic counselor.

How do I sign up for a MyRisk result consult?

1. Visit my.myriad.com/consults where you can register for an account.
2. You will be directed to schedule your consult with a certified genetic counselor.

Please note you will need to know the Accession # from your report in order to sign up for a session. Write it down for your reference below:

_ _ _ _ _ _ _ _ -BLD

3. After signing up for a consult, you will receive an email confirmation.
4. If you need to make any changes to your consult session, you can do so via your account or your email address.

Need help registering for a consult?

Feel free to reach out to a Myriad Medical Information Liaison by calling (800) 469-7423 (ext 3850) or emailing helpmed@myriad.com.

Myriad genetics

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108

myriad.com